Section Arrow
MCRB.NASDAQ
- Seres Therapeutics Inc
Quotes are at least 15-min delayed:2025/12/22 05:46 EST
Pre Market
Last
 --
-- (--)
Bid
14
Ask
16.4
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 14.98
-0.3 (-1.96%)
Day High 
15.7882 
Prev. Close
15.28 
1-M High
29.98 
Volume 
169.67K 
Bid
14
Ask
16.4
Day Low
14.03 
Open
15.22 
1-M Low
15.1 
Market Cap 
138.23M 
Currency 美元 
P/E 17.36 
%Yield -- 
10-SMA 16.45 
20-SMA 17.1 
50-SMA 17.49 
52-W High 29.98 
52-W Low 6.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.30/-10.43
Enterprise Value
221.20M
Balance Sheet
Book Value Per Share
4.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
14.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.18+3.29+30.21%-- 
Pre Market 14.19 +0.01 +0.07%
RXRXRecursion Pharmaceuticals4.26-0.18-4.05%-- 
Pre Market 4.4 +0.14 +3.29%
IBRXImmunityBio2.08-0.01-0.48%-- 
Pre Market 2.13 +0.05 +2.40%
PBMPsyence Biomedical Ltd1-0.46-31.51%0.04PE
Pre Market 1.01 +0.01 +1.00%
GOVXGeoVax Labs0.1592-0.0809-33.69%-- 
Pre Market 0.1545 -0.0047 -2.95%
Industry overview quotes are at least 15 minutes delayed
Business Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by thecompany are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.